<DOC>
	<DOCNO>NCT01720901</DOCNO>
	<brief_summary>To evaluate efficacy safety increase dose icotinib advance NSCLC patient progress gefitinib therapy .</brief_summary>
	<brief_title>Increased Dose Icotinib Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy</brief_title>
	<detailed_description>This single center , single arm open label study design ass safety efficacy use high dose Icotinib ( Conmana ) way treat patient non-small cell lung cancer progress routine gefitinib therapy progression-free survival , well overall survival disease control rate . The adverse event adverse reaction evaluate well .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Histologically cytologically confirm local advance metastatic stage IIIB/IV NSCLC . Have treat gefitinib achieve complete response , partial remission , stable disease within 3 month first dose gefitinib . At least one measurable lesion accord Response Evaluation Criteria Solid Tumors . Signed date informed consent start specific protocol procedure . Allergic icotinib . Gefitinib except , experience Antitumor Monoclonal Antibody small molecular compound therapy erlotinib Cetuximab . Severe systemic disease control unstable uncompensated respiratory , cardiac , liver , renal disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>